EUVIMEDEUVIMED entdecken
Crossref

Pharmacogenomic Testing in Oncology: A Health System’S Approach to Identify Oncology Provider Perspectives

Meghna Bhatt, Beth N Peshkin iD, Sadaf Kazi iD, Marc D Schwartz, Nadia Ashai, Sandra M Swain iD, D Max Smith iD

Pharmacogenomics · 2023

DOI: 10.2217/pgs-2023-0164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Meghna Bhatt und 6 weiteren Autor:innen. Beteiligte Einrichtung: MedStar Health, Columbia, MD 21044, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Pharmacogenetics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials & methods: A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System.

Results

25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394).

Conclusion

Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingPharmacogeneticsHumansMedical Oncology

Stichwörter der Autor:innen

oncologypharmacogeneticspharmacogenomicspharmacysurvey

Autor:innen und Institutionen

  • MedStar Health, Columbia, MD 21044, USA.
  • Cancer Prevention & Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.
  • National Center for Human Factors in Healthcare, MedStar Health Research Institute, Washington, DC 20008, USA.
  • Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.
  • Department of Medicine, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA.

ORCID-Profile: Beth N Peshkin, Sadaf Kazi, Sandra M Swain, D Max Smith

Zitieren

APA

Bhatt, M., Peshkin, B. N., Kazi, S., Schwartz, M. D., Ashai, N., Swain, S. M., & Smith, D. M. (2023). Pharmacogenomic Testing in Oncology: A Health System’S Approach to Identify Oncology Provider Perspectives. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0164

Vancouver

Bhatt M, Peshkin BN, Kazi S, Schwartz MD, Ashai N, Swain SM, et al. Pharmacogenomic Testing in Oncology: A Health System’S Approach to Identify Oncology Provider Perspectives. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0164

BibTeX
@article{Bhatt2023,
  author = {Bhatt, Meghna and Peshkin, Beth N and Kazi, Sadaf and Schwartz, Marc D and Ashai, Nadia and Swain, Sandra M and Smith, D Max},
  title = {Pharmacogenomic Testing in Oncology: A Health System’S Approach to Identify Oncology Provider Perspectives},
  journal = {Pharmacogenomics},
  year = {2023},
  doi = {10.2217/pgs-2023-0164}
}
Kostenlos starten →